- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04183166
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
April 19, 2024 updated by: Transgene
A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Transgene EU, Clinical Operations Department
- Phone Number: + 33.3.88.27.91.00
- Email: clinical.trials@transgene.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Not yet recruiting
- Hopital Saint Andre - CHU de Bordeaux
-
Principal Investigator:
- Dr Daste
-
Marseille, France, 13000
- Not yet recruiting
- Hopital De La Timone
-
Principal Investigator:
- Pr Salas
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Principal Investigator:
- Pr Le Tourneau
-
Toulouse, France, 31100
- Recruiting
- IUCT Toulouse
-
Principal Investigator:
- Pr Delord
-
Villejuif, France, 94805
- Not yet recruiting
- Institut Gustave Roussy
-
Principal Investigator:
- Dr Even
-
-
-
-
-
Bebington, United Kingdom, CH63 4JY
- Recruiting
- NHS Clatterbridge Cancer Center
-
Principal Investigator:
- Pr Ottensmeier
-
Cardiff, United Kingdom, CF14 2TL
- Not yet recruiting
- Velindre Cancer Centre NHS Trust
-
Principal Investigator:
- Dr Evans
-
Liverpool, United Kingdom, L9 7AL
- Recruiting
- Aintree University Hospital NHS Fondation Trust
-
Principal Investigator:
- Pr Jones
-
Southampton, United Kingdom, SO16 6YD
- Recruiting
- University Hospital NHS Fondation Trust
-
Principal Investigator:
- Dr Karydis
-
-
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic Jacksonville
-
Principal Investigator:
- Dr Zhao
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed written informed consent
- Newly diagnosed stage III or IV, amenable to surgery (AJCC 8th edition) squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
- Female or male patients, aged at least 18 years
- Patients in Complete Response after treatment of their primary tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- Adequate hematological, hepatic and renal functions
Exclusion Criteria:
- Patients with carcinoma of the nasopharynx, squamous cell-carcinoma of unknown primary, squamous cell carcinoma that originates from the skin and salivary gland or paranasal sinus, non-squamous histologies.
- Prior exposure to anti-cancer vaccines and any antibody targeting T-cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA4 antibodies.
- Other active malignancy requiring concurrent systemic intervention.
- Patients with previous malignancies other than the target malignancy to be investigated in this trial
- Known history of positive testing for Human Immunodeficiency Virus (HIV) or known Acquired Immune Deficiency Syndrome (AIDS)
- Clinical or laboratory history or evidence of Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) indicating acute or chronic infection
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 10 mIU/mL)
- Treatment with another investigational agent since the beginning of the screening period
- Uncontrolled intercurrent illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A : Early study treatment initiation
TG4050 treatment initiation at completion of primary treatment
|
Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
|
Experimental: Arm B: Study treatment initiation at recurrence
TG4050 treatment initiation at the time of recurrence
|
Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5)
Time Frame: Up to 2 Years.
|
Incidence of Adverse Event reported per CTCAE v5.
|
Up to 2 Years.
|
Phase I/II: Disease-Free Survival
Time Frame: Up to 2 years.
|
Time from randomization to documented recurrence of disease.
|
Up to 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Disease-Free Survival
Time Frame: Up to 2 Years.
|
Time from randomization to documented recurrence of disease.
|
Up to 2 Years.
|
Phase I: Tumor response rate
Time Frame: Up to 2 years.
|
Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to RECIST version 1.1 criteria.
|
Up to 2 years.
|
Phase I/II: Safety and tolerability (Adverse Event reported per CTCAE v5)
Time Frame: Up to 2 years.
|
Incidence of Adverse Event reported per CTCAE v5.
|
Up to 2 years.
|
Phase I/II: Distant Metastases-Free Survival
Time Frame: Up to 2 years.
|
Time from randomization to documented first occurrence of distant metastasis.
|
Up to 2 years.
|
Phase I/II: Loco-Regional Relapse-Free Survival
Time Frame: Up to 2 years.
|
Time from randomization to documented loco-regional recurrence.
|
Up to 2 years.
|
Phase I/II: Overall Response Rate in patients with recurrent disease
Time Frame: Up to 2 years.
|
Percentage of patients with a best overall response of complete response or partial response according to RECIST, version 1.1 criteria.
|
Up to 2 years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 12, 2019
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
December 30, 2028
Study Registration Dates
First Submitted
November 21, 2019
First Submitted That Met QC Criteria
November 27, 2019
First Posted (Actual)
December 3, 2019
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TG4050.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of Head and Neck
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
University of PittsburghNational Cancer Institute (NCI)TerminatedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
James J LeeAVEO Pharmaceuticals, Inc.CompletedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
Clinical Trials on TG4050
-
TransgeneActive, not recruitingFallopian Tube Cancer | Peritoneal Carcinoma | Ovarian CarcinomaUnited States, France